By Fineline Cube 
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its Category 1 small molecule drug HS-10529. The drug targets the KRAS G12D mutation and is intended for the treatment of advanced solid tumors, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
HS-10529: Targeting KRAS G12D
HS-10529 is a novel small molecule drug designed to target the KRAS G12D mutation, which is commonly found in several aggressive cancers. By specifically inhibiting this mutation, HS-10529 aims to provide a new therapeutic option for patients with limited treatment choices. The approval marks a significant step forward in Hansoh’s oncology pipeline, expanding its footprint in the field of precision medicine.
Clinical Trial and Future Outlook
With clinical approval secured, Hansoh is poised to initiate trials to evaluate the safety and efficacy of HS-10529 in patients with KRAS G12D-mutated cancers. This development underscores Hansoh’s commitment to innovation and its focus on addressing unmet medical needs in oncology.-Fineline Info & Tech